Medtronic intros new diabetes report for its professional-grade CGM

iPro 2 Professional CGM device--Courtesy of Medtronic

Medtronic ($MDT) has introduced a new report that offers physicians an interpretation of detailed glucose data over time. The one-page report is intended to identify a patient's main issues with glucose control and their potential causes--which is expected to better enable their doctor to manage them.

The new CareLink iPro report is called Pattern Snapshot and is for Medtronic's iPro 2 Professional CGM system; that device is a professional-grade continuous glucose monitor (CGM) that's used by a physician to monitor a diabetic patient's glucose level continuously for up to three days and is designed to offer just these sorts of longitudinal insights that can serve as the basis of improved patient care.

"We developed this rule-based, simplified report to enhance the use of professional CGM as part of the overall diabetes management regimen," Laura Stoltenberg, general manager of Medtronic's Non-Intensive Diabetes Therapies business unit, said in a statement. "Healthcare professionals will now have a simplified report that will allow for faster interpretation of the most important diabetes metrics, so they can quickly uncover their patient's most important issues."

iPro dashboard--Courtesy of Medtronic

Pattern Snapshot identifies the top three issues in a patient's glucose profile, providing details of each priority issue. This includes possible causes for each pattern, as well as visuals of meal times and daily glucose values, thereby allowing physicians to uncover more information in less time. Professional-grade CGM use is becoming more common and can be routinely used by healthcare providers to capture more episodes of low blood sugar to better understand impediments to glycemic control.

"The retrospective CGM technology of Medtronic's iPro2 Professional CGM presents the patient and provider with accurate information that allows personalized treatment decisions. This comprehensive yet easy-to-interpret continuous glycemic data will arm the care team with valuable and previously difficult to obtain data," added Dr. Todd Zeiger, VP of UH Primary Care Institute in Cincinnati, OH.

- here is the announcement

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.